Fig. 1 · Structure

Documents & Downloads

AT7519

Cat. No. A10093 CAS 844442-38-2

CDK Inhibitor

AT7519 is an inhibitor of multiple cyclin-dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation.

In Stock

Publications for AT7519

1 publication citing this product

  1. Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

AT7519 inhibits multiple CDKs in cell-free assays, including CDK9/cyclin T (IC50 <10 nM), CDK5/p35 (13 nM), and CDK2/cyclin A (47 nM). Activity against GSK3β (89 nM) limits a CDK-selective interpretation. [1]

Live-cell profiling also found broad CDK engagement by AT7519. Target-engagement IC50 values depend on the cellular assay and regulatory partner and should not be substituted for cell-free enzyme potencies. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
CDK9/CyclinT IC50 <10nM
CDK5/p35 IC50 13nM
CDK2/CyclinA IC50 47nM
GSK-3β IC50 89nM
CDK4/CyclinD1 IC50 100nM
CDK6/CyclinD3 IC50 170nM
CDK1/CyclinB IC50 210nM
CDK3/CyclinE IC50 360nM
PI3Kβ IC50 >1μM
PLK3 IC50 >1μM
RET IC50 >1μM
SGK IC50 >1μM
TrkB IC50 >1μM
JAK2 IC50 >1μM
CDK7/CyclinH/MAT1 IC50 2.4μM
SAPK2A(p38α) IC50 >10μM
p70S6K IC50 >10μM
PDGFR IC50 >10μM
PDK-1 IC50 >10μM
PKBβ IC50 >10μM
VEGFR1 IC50 >10μM
AuroraA IC50 >10μM
c-Abl IC50 >10μM
c-Src IC50 >10μM
Chk1 IC50 >10μM
EGFR IC50 >10μM
FGFR3 IC50 >10μM
IR IC50 >10μM
JNK2 IC50 >10μM
MAPK1 IC50 >10μM
MEK1 IC50 >10μM
Met IC50 >10μM

32 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
A2058 IC50 0.166 μM Antiproliferative activity against human A2058 cells assessed as reduction in cell viability measured after 96 hrs by Celltiter-Glo luminescent assay [PMID: 33611192]
A2780 IC50 350 nM Antiproliferative activity against human A2780 cells assessed as cell viability after 72 hrs by alamar blue assay [PMID: 18656911]
ASPC1 IC50 533 nM Antiproliferative activity against human AsPC1 cells after 72 hrs by prestoblue assay [PMID: 30343954]
BXPC-3 IC50 640 nM Antiproliferative activity against human BxPC3 cells after 72 hrs by prestoblue assay [PMID: 30343954]
HCT-116 IC50 0.082 μM Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by alamar blue assay [PMID: 18656911]
HCT-116 IC50 132 nM Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by cell titer glo-based luminescence assay [PMID: 31175010]
HCT-116 IC50 80 nM Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by Alamar blue assay [PMID: 26115571]
MIA PaCa-2 IC50 411 nM Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by prestoblue assay [PMID: 30343954]
MRC5 IC50 > 10000 nM Antiproliferative activity against human MRC5 nonprolifreative cells assessed as cell viability after 72 hrs by alamar blue assay [PMID: 18656911]
MRC5 IC50 0.425 μM Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 96 hrs by Celltiter-Glo luminescent assay [PMID: 33611192]
MRC5 IC50 980 nM Antiproliferative activity against human MRC5 cells assessed as cell viability after 72 hrs by alamar blue assay [PMID: 18656911]
MV4-11 IC50 0.391 μM Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability measured after 96 hrs by Celltiter-Glo luminescent assay [PMID: 33611192]
PC-3 IC50 0.71 μM Antiproliferative activity against AR-negative human PC3 cells assessed as reduction in cell viability after 5 days by CCK8 assay [PMID: 31846828]
Sf21 IC50 < 10 nM Inhibition of recombinant human full-length C-terminal His6-tagged CDK9/human full-length untagged cyclin T1 expressed in baculovirus infected Sf21 insect cells using PDKtide as substrate [PMID: 30543440]
Sf21 IC50 210 nM Inhibition of recombinant full-length human C-terminal His6-tagged CDK1/human full-length N-terminal GST-tagged Cyclin B expressed in baculovirus infected Sf21 insect cells using histone H1 as substrate measured after 2 hrs in presence of gamma[32P] ATP b [PMID: 30543440]
Sf21 IC50 2400 nM Inhibition of recombinant human C-terminal His6-tagged full length CDK7/untagged recombinant full length human Cyclin H/N-terminal GST-tagged recombinant full length human MAT1 expressed in baculovirus infected Sf21 insect cells using cdk7 peptide as subs [PMID: 30543440]
Sf21 IC50 360 nM Inhibition of recombinant human full-length C-terminal His6-tagged CDK3/full-length human N-terminal GST-tagged Cyclin E expressed in baculovirus infected Sf21 insect cells using histone H1 as substrate [PMID: 30543440]

17 records · Scroll to view more

AT7519 Research Summary

This section summarizes 3 in vitro studies and 2 in vivo studies of AT7519 from 3 published references. In vitro models include isolated CDK/cyclin complexes and GSK3β; 20 MYCN-amplified and 9 non-MYCN-amplified neuroblastoma cell lines. In vivo models include female NMRI nu/nu mice bearing MYCN-amplified AMC711T xenografts.

AT7519 In Vitro Studies

In a neuroblastoma panel, MYCN-amplified lines had lower median 72 h viability IC50 values than non-amplified lines (386 versus 1227 nmol/L). The corresponding median LC50 values were 1.7 and 8.1 µmol/L. [3]

Cell-free kinase inhibition panel

Biochemical assay · Isolated CDK/cyclin complexes and GSK3β [1]

AT7519 inhibited multiple CDKs and GSK3β; potency varied by kinase and assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CDK1/cyclin B activityIC50 210 nM[1]
CDK2/cyclin A activityIC50 47 nM[1]
CDK3/cyclin E activityIC50 360 nM[1]
CDK4/cyclin D1 activityIC50 100 nM[1]
CDK5/p35 activityIC50 13 nM[1]
CDK6/cyclin D3 activityIC50 170 nM[1]
CDK7/cyclin H/MAT1 activityIC50 2400 nM[1]
CDK9/cyclin T activityIC50 <10 nM[1]
GSK3β activityIC50 89 nM[1]
Aurora A activityIC50 >10000 nM[1]

Literature-Reported Treatment Conditions

Exposure duration
Assay-dependent: CDK1 2 h; CDK2 4 h; CDK4/5/6 30 min; GSK3β 3 h; Aurora A 30 min.
Method
Cell-free concentration-response kinase assays; IC50 fitted from replicate curves in GraphPad Prism.
Vehicle
2.5% DMSO reported for CDK4/6 assays only.
Reported limits
Compound concentration series, exact replicate n and uncertainty not specified in SI; external CDK3/7/9 assay conditions and salt form not specified. No recommended working concentration inferred.
Methods and source locations

Compound reported in the paper: AT7519; Compound label in the paper: AT7519

Compound-level research findings; no claim of Adooq lot testing or salt/formulation equivalence.

Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)

CDK1/cyclin B activity: Radiometric filter-binding assay; histone H1; 45 µM ATP; 2 h. — Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)

CDK2/cyclin A activity: Radiometric filter-binding assay; histone H1; 45 µM ATP; 4 h. — Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)

CDK3/cyclin E activity: External kinase assay; detailed conditions not provided in retrieved SI. — Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)

CDK4/cyclin D1 activity: ELISA-format GST-pRb phosphorylation assay; 30 min; 2.5% DMSO; ATP concentration not stated in SI. — Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)

CDK5/p35 activity: DELFIA phosphorylation assay; biotinylated histone H1 peptide; 15 µM ATP; 30 min. — Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)

CDK6/cyclin D3 activity: ELISA-format GST-pRb phosphorylation assay; 30 min; 2.5% DMSO; ATP concentration not stated in SI. — Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)

CDK7/cyclin H/MAT1 activity: External kinase assay; detailed conditions not provided in retrieved SI. — Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)

CDK9/cyclin T activity: External kinase assay; detailed conditions not provided in retrieved SI. — Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)

GSK3β activity: Radiometric assay; glycogen synthase peptide 2; 15 µM ATP; 3 h. — Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)

Aurora A activity: Radiometric assay; Kemptide; 15 µM ATP; 30 min. — Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)

Live-cell CDK target engagement

Cell-based study · HEK-293 cells expressing NanoLuc-CDK fusions with indicated regulatory partners [2]

AT7519 engaged multiple CDK complexes in living cells. These IC50 values measure tracer displacement, not enzyme inhibition or cell viability.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CDK2/E1 target engagementIC50 580 nM[2]
CDK4/D1 target engagementIC50 730 nM[2]
CDK6/D1 target engagementIC50 700 nM[2]
CDK7 target engagementIC50 120 nM[2]
CDK9/K target engagementIC50 120 nM[2]
CDK11a/L2 target engagementIC50 140 nM[2]
CDK11b/L2 target engagementIC50 81.76 nM[2]
CDK14/Y target engagementIC50 730 nM[2]
CDK15/Y target engagementIC50 460 nM[2]
CDK16/Y target engagementIC50 99.5 nM[2]
CDK17/Y target engagementIC50 48 nM[2]
CDK18/Y target engagementIC50 500 nM[2]

Literature-Reported Treatment Conditions

Treatment concentration
Initial screen: 10 µM; follow-up: 11-point dilution series with maximum 10 µM.
Exposure duration
2 h equilibration before BRET measurement.
Method
Live-cell competitive BRET assay.
Vehicle
DMSO stock diluted in Opti-MEM; final DMSO percentage not specified.
Co-treatment
Tracer co-incubation is an assay component, not a therapeutic combination.
Reported limits
Exact dilution points and final DMSO percentage not extracted. Blank potency cells reflect reporting thresholds, not proof of inactivity.
Methods and source locations

Compound reported in the paper: AT7519; Compound label in the paper: AT7519

Compound-level research findings; no claim of Adooq lot testing or salt/formulation equivalence.

Supplementary Data 1 row 33; Data 2 row 10, headers rows 3–5 and footnote A53; Data 3 row 8 and footnote A51; Methods: Cell transfections and BRET measurements; Determination of test compound occupancy and potency; Test compound formulation and testing strategy

CDK2/E1 target engagement: BRET competitive tracer displacement; reported mean of two independent experiments (AT7519 row); no SEM given. Partner labels follow original dataset. — Supplementary Data 1 row 33; Data 2 row 10, headers rows 3–5 and footnote A53; Data 3 row 8 and footnote A51; Methods: Cell transfections and BRET measurements; Determination of test compound occupancy and potency; Test compound formulation and testing strategy

CDK4/D1 target engagement: BRET competitive tracer displacement; reported mean of two independent experiments (AT7519 row); no SEM given. Partner labels follow original dataset. — Supplementary Data 1 row 33; Data 2 row 10, headers rows 3–5 and footnote A53; Data 3 row 8 and footnote A51; Methods: Cell transfections and BRET measurements; Determination of test compound occupancy and potency; Test compound formulation and testing strategy

CDK6/D1 target engagement: BRET competitive tracer displacement; reported mean of two independent experiments (AT7519 row); no SEM given. Partner labels follow original dataset. — Supplementary Data 1 row 33; Data 2 row 10, headers rows 3–5 and footnote A53; Data 3 row 8 and footnote A51; Methods: Cell transfections and BRET measurements; Determination of test compound occupancy and potency; Test compound formulation and testing strategy

CDK7 target engagement: BRET competitive tracer displacement; reported mean of two independent experiments (AT7519 row); no SEM given. Partner labels follow original dataset. — Supplementary Data 1 row 33; Data 2 row 10, headers rows 3–5 and footnote A53; Data 3 row 8 and footnote A51; Methods: Cell transfections and BRET measurements; Determination of test compound occupancy and potency; Test compound formulation and testing strategy

CDK9/K target engagement: BRET competitive tracer displacement; reported mean of two independent experiments (AT7519 row); no SEM given. Partner labels follow original dataset. — Supplementary Data 1 row 33; Data 2 row 10, headers rows 3–5 and footnote A53; Data 3 row 8 and footnote A51; Methods: Cell transfections and BRET measurements; Determination of test compound occupancy and potency; Test compound formulation and testing strategy

CDK11a/L2 target engagement: BRET competitive tracer displacement; reported mean of two independent experiments (AT7519 row); no SEM given. Partner labels follow original dataset. — Supplementary Data 1 row 33; Data 2 row 10, headers rows 3–5 and footnote A53; Data 3 row 8 and footnote A51; Methods: Cell transfections and BRET measurements; Determination of test compound occupancy and potency; Test compound formulation and testing strategy

CDK11b/L2 target engagement: BRET competitive tracer displacement; reported mean of two independent experiments (AT7519 row); no SEM given. Partner labels follow original dataset. — Supplementary Data 1 row 33; Data 2 row 10, headers rows 3–5 and footnote A53; Data 3 row 8 and footnote A51; Methods: Cell transfections and BRET measurements; Determination of test compound occupancy and potency; Test compound formulation and testing strategy

CDK14/Y target engagement: BRET competitive tracer displacement; reported mean of two independent experiments (AT7519 row); no SEM given. Partner labels follow original dataset. — Supplementary Data 1 row 33; Data 2 row 10, headers rows 3–5 and footnote A53; Data 3 row 8 and footnote A51; Methods: Cell transfections and BRET measurements; Determination of test compound occupancy and potency; Test compound formulation and testing strategy

CDK15/Y target engagement: BRET competitive tracer displacement; reported mean of two independent experiments (AT7519 row); no SEM given. Partner labels follow original dataset. — Supplementary Data 1 row 33; Data 2 row 10, headers rows 3–5 and footnote A53; Data 3 row 8 and footnote A51; Methods: Cell transfections and BRET measurements; Determination of test compound occupancy and potency; Test compound formulation and testing strategy

CDK16/Y target engagement: BRET competitive tracer displacement; reported mean of two independent experiments (AT7519 row); no SEM given. Partner labels follow original dataset. — Supplementary Data 1 row 33; Data 2 row 10, headers rows 3–5 and footnote A53; Data 3 row 8 and footnote A51; Methods: Cell transfections and BRET measurements; Determination of test compound occupancy and potency; Test compound formulation and testing strategy

CDK17/Y target engagement: BRET competitive tracer displacement; reported mean of two independent experiments (AT7519 row); no SEM given. Partner labels follow original dataset. — Supplementary Data 1 row 33; Data 2 row 10, headers rows 3–5 and footnote A53; Data 3 row 8 and footnote A51; Methods: Cell transfections and BRET measurements; Determination of test compound occupancy and potency; Test compound formulation and testing strategy

CDK18/Y target engagement: BRET competitive tracer displacement; reported mean of two independent experiments (AT7519 row); no SEM given. Partner labels follow original dataset. — Supplementary Data 1 row 33; Data 2 row 10, headers rows 3–5 and footnote A53; Data 3 row 8 and footnote A51; Methods: Cell transfections and BRET measurements; Determination of test compound occupancy and potency; Test compound formulation and testing strategy

Neuroblastoma viability by MYCN amplification status

Cell-based study · 20 MYCN-amplified and 9 non-MYCN-amplified neuroblastoma cell lines [3]

MYCN-amplified lines were more sensitive. IC50 uses the 72 h vehicle control; LC50 uses pretreatment viability as its baseline.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MYCN-amplified median IC50IC50 386 nmol/L[3]
Non-MYCN-amplified median IC50IC50 1227 nmol/L[3]
MYCN-amplified median LC50LC50 1.7 µmol/L[3]
Non-MYCN-amplified median LC50LC50 8.1 µmol/L[3]

Literature-Reported Treatment Conditions

Treatment concentration
0.64 nmol/L–10 µmol/L, five-fold dilution steps.
Exposure duration
72 h; baseline viability also measured before treatment.
Method
MTT concentration-response assay.
Vehicle
0.1% DMSO control.
Co-treatment
AT7519 alone.
Reported limits
Individual cell-line values and culture details in SI were not retrieved. Median IC50/LC50 values are measurements, not recommended doses.
Methods and source locations

Compound reported in the paper: AT7519; Compound label in the paper: AT7519

Compound-level research findings; no claim of Adooq lot testing or salt/formulation equivalence.

Methods: Chemicals and IC50 and LC50; Results: Neuroblastoma cells with MYCN amplification are sensitized to AT7519 treatment; Figure 1 and legend

MYCN-amplified median IC50: MTT; triplicate wells; group medians across cell lines. One-tailed unpaired Student’s t-test: IC50 P=0.0074; LC50 P=0.0053. — Methods: Chemicals and IC50 and LC50; Results: Neuroblastoma cells with MYCN amplification are sensitized to AT7519 treatment; Figure 1 and legend

Non-MYCN-amplified median IC50: MTT; triplicate wells; group medians across cell lines. One-tailed unpaired Student’s t-test: IC50 P=0.0074; LC50 P=0.0053. — Methods: Chemicals and IC50 and LC50; Results: Neuroblastoma cells with MYCN amplification are sensitized to AT7519 treatment; Figure 1 and legend

MYCN-amplified median LC50: MTT; triplicate wells; group medians across cell lines. One-tailed unpaired Student’s t-test: IC50 P=0.0074; LC50 P=0.0053. — Methods: Chemicals and IC50 and LC50; Results: Neuroblastoma cells with MYCN amplification are sensitized to AT7519 treatment; Figure 1 and legend

Non-MYCN-amplified median LC50: MTT; triplicate wells; group medians across cell lines. One-tailed unpaired Student’s t-test: IC50 P=0.0074; LC50 P=0.0053. — Methods: Chemicals and IC50 and LC50; Results: Neuroblastoma cells with MYCN amplification are sensitized to AT7519 treatment; Figure 1 and legend

AT7519 In Vivo Studies

AT7519 inhibited AMC711T xenograft growth and produced regression in Th-MYCN tumors. Responses were not durable: xenografts regrew after treatment withdrawal, and Th-MYCN tumors relapsed during treatment. Reported doses concern the study material; its salt form was not specified. [3]

AMC711T xenograft growth inhibition

Animal study · Female NMRI nu/nu mice bearing MYCN-amplified AMC711T xenografts [3]

Growth inhibition was dose-dependent; 15 mg/kg did not significantly improve efficacy over 10 mg/kg. Tumors grew more rapidly after treatment stopped.

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Once daily, five days on/two days off
Treatment course
Up to three consecutive weeks
Vehicle
Saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
5 mg/kg/day AT7519Saline vehicleSignificant growth inhibition versus saline.[3]
10 mg/kg/day AT7519Saline vehicleTumor growth nearly blocked; greater inhibition than 5 mg/kg.[3]
15 mg/kg/day AT7519Saline vehicleTumor growth nearly blocked; no significant efficacy improvement over 10 mg/kg.[3]
5 mg/kg/day AT7519
Model: AMC711T xenografts
Reported limits: n=8 Saline n=10; tumor-volume data mean ± SEM. Salt form and free-base-equivalent dose convention not stated in retrieved paper.
10 mg/kg/day AT7519
Model: AMC711T xenografts
Reported limits: n=8 Saline n=10; tumor-volume data mean ± SEM. Salt form and free-base-equivalent dose convention not stated in retrieved paper.
15 mg/kg/day AT7519
Model: AMC711T xenografts
Reported limits: n=11 Saline n=10; tumor-volume data mean ± SEM. Salt form and free-base-equivalent dose convention not stated in retrieved paper.
Methods and source locations

Compound reported in the paper: AT7519; Compound label in the paper: AT7519

Compound-level research findings; no claim of Adooq lot testing or salt/formulation equivalence.

Methods: Chemicals; In vivo efficacy in neuroblastoma xenograft mouse models; Results: AT7519 inhibits the growth of MYCN-amplified neuroblastoma xenografts; Figure 3A and legend

5 mg/kg/day AT7519 · Methods: Chemicals; In vivo efficacy in neuroblastoma xenograft mouse models; Results: AT7519 inhibits the growth of MYCN-amplified neuroblastoma xenografts; Figure 3A and legend

10 mg/kg/day AT7519 · Methods: Chemicals; In vivo efficacy in neuroblastoma xenograft mouse models; Results: AT7519 inhibits the growth of MYCN-amplified neuroblastoma xenografts; Figure 3A and legend

15 mg/kg/day AT7519 · Methods: Chemicals; In vivo efficacy in neuroblastoma xenograft mouse models; Results: AT7519 inhibits the growth of MYCN-amplified neuroblastoma xenografts; Figure 3A and legend

Th-MYCN tumor response and survival

Animal study · Th-MYCN transgenic mice with palpable tumors, randomized to AT7519 or saline [3]

Tumor regression and prolonged survival were reported, but mice relapsed during AT7519 treatment.

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Once daily, five days on/two days off
Treatment course
Up to three consecutive weeks
Vehicle
Saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
15 mg/kg/day AT7519Saline vehicleMean tumor-volume reduction approximately 86% at day 7; 6/7 partial responses and 1/7 very good partial response. Saline tumors increased approximately 218%. Survival improved (log-rank P=0.0004); relapse occurred on treatment.[3]
15 mg/kg/day AT7519
Model: Th-MYCN transgenic mice
Reported limits: Day-7 response: 7 treated mice; survival analysis: AT7519 n=6, saline n=8. These endpoint populations are not equated. Salt form and free-base-equivalent dose convention not stated in retrieved paper.
Methods and source locations

Compound reported in the paper: AT7519; Compound label in the paper: AT7519

Compound-level research findings; no claim of Adooq lot testing or salt/formulation equivalence.

Methods: In vivo efficacy in Th-MYCN transgenic mice; Results: AT7519 causes tumour volume reduction in Th-MYCN transgenic mice; Figure 4A–C and legend

15 mg/kg/day AT7519 · Methods: In vivo efficacy in Th-MYCN transgenic mice; Results: AT7519 causes tumour volume reduction in Th-MYCN transgenic mice; Figure 4A–C and legend

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 844442-38-2
Applications CDK Inhibitor
Formula C16H17Cl2N5O2
Molecular Weight 382.2
SMILES
C1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 9 mg/mL (23.54 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
1 mg/mL
Vehicle
2% DMSO+30% PEG 300+2% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

AT7519 Research References

  1. [1] Squires MS, Feltell RE, Wallis NG, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Molecular cancer therapeutics (2009). PMID: 19174555 DOI: 10.1158/1535-7163.mct-08-0890 Source material
  2. [2] Wells CI, Vasta JD, Corona CR, et al. Quantifying CDK inhibitor selectivity in live cells. Nature communications (2020). PMID: 32488087 DOI: 10.1038/s41467-020-16559-0 Source material
  3. [3] Dolman ME, Poon E, Ebus ME, et al. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 26202950 DOI: 10.1158/1078-0432.ccr-15-0313 Source material

Publications

1 publication citing this product

  1. Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418

Added to your cart

View Cart Checkout
Loading...